Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 2, 2012, Pages 193-199

  Lasseter, K ^a   Dilzer, S ^a   Jansat, J M ^b   Garcia Gil, E ^b   Caracta, C F ^c   Ortiz, S ^c  

^a Clinical Pharmacology of Miami Inc   (United States)

^b SA Research Centre ^*  (Spain)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Aclidinium bromide; COPD; Pharmacokinetics; Safety

Indexed keywords

ACLIDINIUM BROMIDE; DRUG METABOLITE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STEADY STATE; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; VITAL SIGN; XEROSTOMIA;

ADOLESCENT; ADULT; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SINGLE-BLIND METHOD; TANDEM MASS SPECTROMETRY; TIME FACTORS; TROPANES; YOUNG ADULT;

EID: 84858289731     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.02.002     Document Type: Article

References (18)

1. Centers for Disease Control and Prevention. Division of vital statistics. deaths: preliminary data for 2008. [Internet]. 2010 Dec [cited 2011 February 3]. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_02.pdf.
2. World Health Organization (WHO). The global burden of disease: 2004 update. [Internet]. 2008 [cited 2011 January 14]. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
3. Barnes P.J. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004, 117(Suppl. 12A):24S-32S.
4. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
5. Sentellas S., Ramos I., Alberti J., Salva M., Anton F., Miralpeix M., et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010, 39:283-290.
6. Alberti J., Martinet A., Sentellas S., Salva M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 2010, 38:1202-1210.
7. Jansat J.M., Lamarca R., Garcia Gil E., Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther 2009, 47:460-468.
8. Ortiz S., Flach S., Caracta C., Garcia Gil E., Jansat J. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male subjects. J Clin Pharmacol 2011 May 31, [Epub]. 10.1177/0091270011406281.
9. Jansat J.M., Lamarca R., de Miquel G., Schrodter A., Miletzki B., Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009, 49:1239-1246.
10. Lasseter K.C., Aubets J., Chuecos F., Garcia Gil E. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol 2010, 51:923-932.
11. Jones PW, Rennard SI, Agusti A, Chanez P, Magnussen H, Fabbri L, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res [Internet]. 2011 April 26 [cited 2011 April 27];12:55. Available from: http://respiratory-research.com/content/12/1/55.
12. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
13. Gavalda A., Miralpeix M., Ramos I., Otal R., Carreno C., Vinals M., et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009, 331:740-751.
14. Fuhr R., Magnussen H., Sarem K., Ribera Llovera A., Kirsten A.-M., Falques M., et al. Efficacy of aclidinium bromide 400 μg BID compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest 2011 Sept 8, [Epub]. 10.1378/chest.11-0406.
15. Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224.
16. Spiriva [package insert] July 2011, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
17. Kerwin E.M., D'Urzo A.D., Gelb A.F., Lakkis H., Garcia Gil E., Caracta C.F. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012 Feb 9, [Epub]. 10.3109/15412555.2012.661492.
18. Jones P.W., Agusti A., Bateman E.D., Singh D., Lamarca R., de Miquel G., et al. Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN. Am J Respir Crit Care Med 2011, 183:A6350. [abstract].